In recent years, some new positron emission tomography (PET) radiopharmaceuticals have come to attention as possible alternatives to fluorine-18-fluoro-2-deoxyglucose (18F-FDG) PET.In this context, this chapter describes the role of PET with gallium-68 (68Ga)-Pentixafor, describing potential clinical indications, with interesting clinical cases. Moreover, synthesis, pharmacokinetics and physiological distribution of 68Ga-Pentixafor, and PET acquisition protocols are described as well.In recent years, some new positron emission tomography (PET) radiopharmaceuticals have come to attention as possible alternatives to fluorine-18-fluoro-2-deoxyglucose (18F-FDG) PET.In this context, this chapter describes the role of PET with gallium-68 (68Ga)-Pentixafor, describing potential clinical indications, with interesting clinical cases. Moreover, synthesis, pharmacokinetics and physiological distribution of 68Ga-Pentixafor, and PET acquisition protocols are described as well
